TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05565807: A Phase Ib/IIa, Open-Label, Dose-Escalation and Extension Study to Evaluate the Safety and Efficacy of An Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor: Zhejiang ACEA Pharmaceutical Co. Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 84 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT05565807 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05565807 Rescue Dossier →